Tags : Bridging Fibrosis

Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study

Tuba Khan April 26, 2019

Shots: The P-III STELLAR 3 study involves assessing of Selonsertib (18mg, 6mg) vs PBO in 802 patients with F3/bridging fibrosis due to NASH in adults aged 18 to 70yrs for […]readmore

Tags : Bridging Fibrosis

Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Bridging Fibrosis

﻿Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study